What type of study is this?

This is a In Vitro Study study.

What question did this study set out to answer?

This research aims to develop LIME, a novel immunotherapy platform using engineered E. coli to enhance anti-tumor immune responses.

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

This research aims to develop LIME, a novel immunotherapy platform using engineered E. coli to enhance anti-tumor immune responses.
Engineered E. coli to express scFvs targeting TAAs and immune receptors.
Assessed bacterial binding and immune activation in vitro using flow cytometry.
Conducted in vivo studies in mouse models to evaluate tumor growth and immune response after treatment.
LIME enhanced T and NK cell activation and cytotoxicity against tumor cells.
In vivo, LIME synergized with anti PD-1 treatment to dramatically reduce tumor growth.
LIME treatment resulted in high tumor engraftment and minimal cytokine release syndrome.

No takes yet. Share an insight, caveat, or question.

Engineering E. coli to target tumor antigens and immune receptors, improving tumor control and reducing cytokine release syndrome.

Bobilev et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark